Negative control of the HGF/c-MET pathway by TGF-β: a new look at the regulation of stemness in glioblastoma
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Negative control of the HGF/c-MET pathway by TGF-β: a new look at the regulation of stemness in glioblastoma
Authors
Keywords
-
Journal
Cell Death & Disease
Volume 8, Issue 12, Pages -
Publisher
Springer Nature
Online
2017-12-13
DOI
10.1038/s41419-017-0051-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O6-Methylguanine–DNA Methyltransferase Biomarker Analyses
- (2017) Timothy Cloughesy et al. JOURNAL OF CLINICAL ONCOLOGY
- A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma
- (2016) Alba A. Brandes et al. NEURO-ONCOLOGY
- Autocrine VEGFR1 and VEGFR2 signaling promotes survival in human glioblastoma models in vitro and in vivo
- (2016) Emese Szabo et al. NEURO-ONCOLOGY
- Toward precision medicine in glioblastoma: the promise and the challenges
- (2015) Michael D. Prados et al. NEURO-ONCOLOGY
- Transforming growth factor-β pathway activity in glioblastoma
- (2015) Karl Frei et al. Oncotarget
- Primary glioblastoma cultures: can profiling of stem cell markers predict radiotherapy sensitivity?
- (2014) Dieter Lemke et al. JOURNAL OF NEUROCHEMISTRY
- EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma
- (2014) Michael Weller et al. LANCET ONCOLOGY
- Differential regulation of TGF-β–induced, ALK-5–mediated VEGF release by SMAD2/3 versus SMAD1/5/8 signaling in glioblastoma
- (2014) Katharina Seystahl et al. NEURO-ONCOLOGY
- Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma
- (2014) A. P. Patel et al. SCIENCE
- EMD 1214063 and EMD 1204831 Constitute a New Class of Potent and Highly Selective c-Met Inhibitors
- (2013) F. Bladt et al. CLINICAL CANCER RESEARCH
- HGF upregulation contributes to angiogenesis in mice with keratinocyte-specific Smad2 deletion
- (2013) Kristina E. Hoot et al. JOURNAL OF CLINICAL INVESTIGATION
- Using the molecular classification of glioblastoma to inform personalized treatment
- (2013) Adriana Olar et al. JOURNAL OF PATHOLOGY
- Astrocytes Enhance the Invasion Potential of Glioblastoma Stem-Like Cells
- (2013) Barbara H. Rath et al. PLoS One
- Studying a Complex Tumor
- (2012) Siyuan Zheng et al. CANCER JOURNAL
- Resistance of Glioblastoma-Initiating Cells to Radiation Mediated by the Tumor Microenvironment Can Be Abolished by Inhibiting Transforming Growth Factor-β
- (2012) Matthew E. Hardee et al. CANCER RESEARCH
- RT-qPCR work-flow for single-cell data analysis
- (2012) Anders Ståhlberg et al. METHODS
- Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background
- (2012) B. R. Davies et al. MOLECULAR CANCER THERAPEUTICS
- Targeting the TGFβ signalling pathway in disease
- (2012) Rosemary J. Akhurst et al. NATURE REVIEWS DRUG DISCOVERY
- Heterogeneity Maintenance in Glioblastoma: A Social Network
- (2011) R. Bonavia et al. CANCER RESEARCH
- MET inhibition in tumor cells by PHA665752 impairs homologous recombination repair of DNA double strand breaks
- (2011) Michaela Medová et al. INTERNATIONAL JOURNAL OF CANCER
- Induction of MET by Ionizing Radiation and Its Role in Radioresistance and Invasive Growth of Cancer
- (2011) Francesca De Bacco et al. JNCI-Journal of the National Cancer Institute
- Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
- (2011) F. M. Yakes et al. MOLECULAR CANCER THERAPEUTICS
- The neurobiology of gliomas: from cell biology to the development of therapeutic approaches
- (2011) Manfred Westphal et al. NATURE REVIEWS NEUROSCIENCE
- A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma
- (2011) P. Y. Wen et al. NEURO-ONCOLOGY
- c-Met signaling induces a reprogramming network and supports the glioblastoma stem-like phenotype
- (2011) Y. Li et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- An overview of the c-MET signaling pathway
- (2011) Shawna Leslie Organ et al. Therapeutic Advances in Medical Oncology
- TGF-β Receptor Inhibitors Target the CD44high/Id1high Glioma-Initiating Cell Population in Human Glioblastoma
- (2010) Judit Anido et al. CANCER CELL
- Targeted therapy for high-grade glioma with the TGF- 2 inhibitor trabedersen: results of a randomized and controlled phase IIb study
- (2010) U. Bogdahn et al. NEURO-ONCOLOGY
- TGF-β Increases Glioma-Initiating Cell Self-Renewal through the Induction of LIF in Human Glioblastoma
- (2009) Silvia Peñuelas et al. CANCER CELL
- Autocrine TGF-β Signaling Maintains Tumorigenicity of Glioma-Initiating Cells through Sry-Related HMG-Box Factors
- (2009) Hiroaki Ikushima et al. Cell Stem Cell
- The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells
- (2009) James W Welsh et al. Radiation Oncology
- Prognostic significance of c-Met expression in glioblastomas
- (2008) Doo-Sik Kong et al. CANCER
- Non-Smad pathways in TGF-β signaling
- (2008) Ying E Zhang CELL RESEARCH
- Transforming Growth Factor- Signaling-Deficient Fibroblasts Enhance Hepatocyte Growth Factor Signaling in Mammary Carcinoma Cells to Promote Scattering and Invasion
- (2008) N. Cheng et al. MOLECULAR CANCER RESEARCH
- EGF regulates plasminogen activator inhibitor-1 (PAI-1) by a pathway involving c-Src, PKCδ, and sphingosine kinase 1 in glioblastoma cells
- (2007) Barbara S. Paugh et al. FASEB JOURNAL
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started